Showing 4081-4090 of 9150 results for "".
- Accelerated Phenotypic Aging Linked to Increased Mortality With PsOhttps://practicaldermatology.com/news/accelerated-phenotypic-aging-linked-to-increased-mortality-with-pso/2483591/A new analysis of US adult data has found that phenotypic age acceleration (PhenoAge-accel) is associated with increased risk of psoriasis and—when coexisting with the disease—elevated risk of all-cause and cardiovascular disease (CVD) mortality. The study, publishe
- FDA Approves Remibrutinib for Adults With CSUhttps://practicaldermatology.com/news/fda-approves-remibrutinib-for-adults-with-csu/2483590/The US Food and Drug Administration (FDA) has approved remibrutinib (Rhapsido, Novartis) as the first oral Bruton’s tyrosine kinase (BTK) inhibitor for the treatment of chronic spontaneous urticaria (CSU) in adults whose symptoms persist despite H1 antihistamine the
- Study: Ruxolitinib Cream Same or Better Than Triamcinolone for Mild to Moderate ADhttps://practicaldermatology.com/news/ruxolitinib-cream-triamcinolone-for-mild-to-moderate-ad/2483574/New analysis of phase 2 data indicates ruxolitinib cream 1.5% may offer comparable or superior efficacy to midpotency corticosteroid triamcinolone 0.1% cream in adult patients with long-standing mild to moderate atopic dermatitis (AD).
- Meta-analysis: Severe Childhood Sunburns Triple Risk of cSCChttps://practicaldermatology.com/news/meta-analysis-severe-childhood-sunburns-triple-risk-of-cscc/2483566/Data from a new meta-analysis showed an association between severe sunburn history and increased risk of cutaneous squamous cell carcinoma (cSCC) across all life stages. Researchers publishing in JAMA Dermatology use
- Roflumilast Phase 2 Results for Children Consistent With Phase 3 Adult Trialshttps://practicaldermatology.com/news/roflumilast-phase-2-results-for-children-consistent-with-phase-3-adult-trials/2483558/Once-daily roflumilast cream 0.3% was well tolerated and improved signs and symptoms of psoriasis in children 2 to 11 years old in two 4-week, phase 2, open-label, maximal usage pharmacokinetic and safety studies, according to an article published in Pediatric Dermatology. The res
- Analysis: Dupilumab-Related Adverse Events Less Common in Black Adults With ADhttps://practicaldermatology.com/news/analysis-dupilumab-related-adverse-events-less-common-in-black-adults-with-ad/2483504/A retrospective chart review in the Journal of Drugs in Dermatology yielded insights into dupilumab-associated adverse events (d-AEs) in Black and African American (AA) adults treated for atopic dermatitis (AD). The st
- From EADV: Rezpegaldesleukin Effective Through 24 Weeks in REZOLVE-AD Trialhttps://practicaldermatology.com/news/from-eadv-rezpegaldesleukin-effective-through-24-weeks-in-rezolve-ad-trial/2483465/New data from the REZOLVE-AD presented at the 2025 European Academy of Dermatology and Venereology (EADV) Congress demonstrated that investigational IL-2 pathway agonist rezpegaldesleukin sustained effect beyond the 16-week induction period in patients with moderat
- FDA Approves Topical Ruxolitinib for AD in Children Aged 2 and Uphttps://practicaldermatology.com/news/fda-approves-topical-ruxolitinib-for-ad-in-children-aged-2-and-up/2483445/The US Food and Drug Administration (FDA) has approved ruxolitinib cream 1.5% (Opzelura) for the short-term and non-continuous chronic treatment of mild-to-moderate atopic dermatitis (AD) in non-immunocompromised children ages 2 and older whose disease is inadequate
- From EADV: Temtokibart Shows Sustained Efficacy in AD; New DELTA TEEN Datahttps://practicaldermatology.com/news/from-eadv-temtokibart-shows-sustained-efficacy-in-ad-new-delta-teen-data/2483428/LEO Pharma announced data from several important trials and presented updates on delgocitinib LEO Pharma presented phase 2b data for its investigational agent temtokibart (LEO 138559) at the 2025 European Academy of Dermatolo
- FDA Clears IND for Rubedo’s GPX4 Modulator in Actinic Keratosishttps://practicaldermatology.com/news/fda-clears-ind-for-rubedos-gpx4-modulator-in-actinic-keratosis/2483388/Rubedo Life Sciences has received FDA clearance for a second Investigational New Drug (IND) application for its lead compound RLS-1496, enabling a Phase 1b/2a trial in patients with actinic keratosis to begin in Q4 2025. Accordi